Compare 10X Genomics Inc (TXG) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs United States Natural Gas Fund — how do they compare? 10X Genomics Inc trades at $80 (market cap $9.92B), while United States Natural Gas Fund trades at $10.75 (market cap $522.93M). The key difference: 10X Genomics Inc is far larger — about 19× United States Natural Gas Fund's market cap, and 10X Genomics Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and United States Natural Gas Fund for 22 Days on average.
| TXG | UNG | |
|---|---|---|
Market Cap | $9.92B | $522.93M |
Volume | 9,372,166 | 33,973,188 |
Sector | Health | Commodities - Energy |
52-Week High | $97.74 | $16.90 |
52-Week Low | $11.48 | $9.63 |
Typical Hold Time | 92 Days | 22 Days |
Enterprise Value | $9.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
UNG trades at $11.03, up 2.7% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported a net income of $65.15 million in 2024, though revenue was $0.00, and maintains a strong balance sheet with total assets of $790.02 million and minimal liabilities. Recent news highlights volatility in natural gas markets due to geopolitical tensions and record U.S. production.
The outlook for UNG is mixed, with bullish technicals and solid profitability offset by revenue uncertainty and market risks. Key opportunities include potential price support from geopolitical events, while risks involve natural gas price fluctuations and high production levels pressuring margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
